These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1356788)

  • 41. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of pramipexole, a dopamine-1/dopamine-2 receptor agonist, on sodium excretion and blood pressure in spontaneously hypertensive rats.
    Kaneko S; Eisner GM; Jose PA
    J Auton Pharmacol; 1990; 10 Suppl 1():s53-60. PubMed ID: 1983009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.
    Natesan S; Svensson KA; Reckless GE; Nobrega JN; Barlow KB; Johansson AM; Kapur S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):810-8. PubMed ID: 16648369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
    Konieczny J; Lenda T; Czarnecka A
    Neuroscience; 2016 Jun; 324():92-106. PubMed ID: 26964686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
    Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
    [No Abstract]   [Full Text] [Related]  

  • 48. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
    Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
    Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers.
    DeWald HA; Heffner TG; Jaen JC; Lustgarten DM; McPhail AT; Meltzer LT; Pugsley TA; Wise LD
    J Med Chem; 1990 Jan; 33(1):445-50. PubMed ID: 1967318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of isomers of hydroxyaporphines on dopamine metabolism in rat brain regions.
    Baldessarini RJ; Marsh ER; Kula NS; Zong RS; Gao YG; Neumeyer JL
    Biochem Pharmacol; 1990 Aug; 40(3):417-23. PubMed ID: 2383279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
    Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
    Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
    Suarez LM; Solis O; Aguado C; Lujan R; Moratalla R
    Cereb Cortex; 2016 Oct; 26(11):4253-4264. PubMed ID: 27613437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.